ADC Weekly Digest - 30 May to 05 June 2026

ADC Weekly Digest - 30 May to 05 June 2026

Regulatory
Innovent Biologics’ IBI343 met primary endpoint in phase 3 Gastric cancer trial with NDA accepted...
Regulatory
SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma
Clinical
MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study
Deals
Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies
Deals
Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions
Deals
Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358